|Adocia SA -- France Stock|| |
EUR 14.76 0.48 3.36%
Member of the Board
Dr. Olivier Martinez serves as a Member of the Board of Directors at Adocia SAS. From 1992 to 1997, he pursued his doctoral studies in cell biology at the Pasteur and Curie Institutes in Paris. After undergoing management training, he joined the Life Science Group of Gemini Consulting and spent two years working on healthcare projects. In 2000 he joined Bioam Gestion as an Associate and became Investment Manager and member of the executive board in 2004. Following the integration of Bioam Gestion into CDC Entreprises in July 2010, he is now in charge of managing investments of the InnoBio and Bioam funds
33 4 72 61 06 10 http://www.adocia.com
Martinez is a graduate of the Ecole Normale Superieure and holds a Ph.D. in cell biology from the University of Paris XI and a diploma from the College des Ingenieurs.
The company has return on total asset (ROA)
of 2.78 %
which means that it generated profit of $2.78 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of 6.98 %
meaning that it generated $6.98 on every $100 dollars invested by stockholders.
The company has accumulated 7 M in total debt with debt to equity ratio (D/E) of 13.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Adocia SA has Current Ratio of 6.29 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Adocia Soci?t? Anonyme, a clinicalstage biotechnology company, develops medicines using therapeutic molecules. Adocia SA (ADOC) is traded on Paris Stock Exchange in France. It is located in Lyon, and employs 119 people.